相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Degradation of proteins by PROTACs and other strategies
Yang Wang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Asparanin A from Asparagus officinalis L. Induces G0/G1 Cell Cycle Arrest and Apoptosis in Human Endometrial Carcinoma Ishikawa Cells via Mitochondrial and PI3K/AKT Signaling Pathways
Fan Zhang et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2020)
Icariside II inhibits tumorigenesis via inhibiting AKT/Cyclin E/CDK 2 pathway and activating mitochondria-dependent pathway
Ya-Sai Sun et al.
PHARMACOLOGICAL RESEARCH (2020)
Icariside II suppresses cervical cancer cell migration through JNK modulated matrix metalloproteinase-2/9 inhibition in vitro and in vivo
Ya-Sai Sun et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment
S. Parylo et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
Baishan Jiang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Selective degradation of CDK6 by a palbociclib based PROTAC
Sandeep Rana et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, invitro and in human tumor xenograft models
Fei Long et al.
CANCER SCIENCE (2019)
Licochalcone B Extracted from Glycyrrhiza uralensis Fisch Induces Apoptotic Effects in Human Hepatoma Cell HepG2
Jun Wang et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2019)
Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer
Joan Cao et al.
ONCOGENE (2019)
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
Laura M. Spring et al.
CURRENT ONCOLOGY REPORTS (2019)
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer
Martin Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Mechanism of Juglone-Induced Cell Cycle Arrest and Apoptosis in Ishikawa Human Endometrial Cancer Cells
Yuan-Yuan Zhang et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2019)
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
Shang Su et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
Takuro Yamamoto et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
The PROTAC technology in drug development
Yutian Zou et al.
CELL BIOCHEMISTRY AND FUNCTION (2019)
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Blake E. Smith et al.
NATURE COMMUNICATIONS (2019)
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Matthias Brand et al.
CELL CHEMICAL BIOLOGY (2019)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships
Yan Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents
Solomon Tadesse et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy
Chuantao Zha et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance
Claire A. Martin et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells
Priyank Patel et al.
MOLECULAR CANCER RESEARCH (2018)
Kinase inhibitors: the road ahead
Fleur M. Ferguson et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Filipa Lynce et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
Radek Jorda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
Z. Ping Lin et al.
FRONTIERS IN ONCOLOGY (2018)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R. Condorelli et al.
ANNALS OF ONCOLOGY (2018)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
CDK4/6 blockade in breast cancer: current experience and future perspectives
Dimitrios Zardavas et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors
Solomon Tadesse et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation
Solomon Tadesse et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
Jiayuan Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Inhibitors of cyclin-dependent kinases as cancer therapeutics
Steven R. Whittaker et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
Shenghui He et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
Erik S. Knudsen et al.
ONCOTARGET (2017)
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
John E. Bisi et al.
ONCOTARGET (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Erik S. Knudsen et al.
TRENDS IN CANCER (2017)
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer
Burak Bilgin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
Cristina Guarducci et al.
BREAST CARE (2017)
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
Dorota Kwapisz
BREAST CANCER RESEARCH AND TREATMENT (2017)
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
Caroline M. Robb et al.
CHEMICAL COMMUNICATIONS (2017)
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
Valerie M. Jansen et al.
CANCER RESEARCH (2017)
CDK4/6 inhibitors in HER2-positive breast cancer
Silvia Paola Corona et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy
Philipp Ottis et al.
ACS CHEMICAL BIOLOGY (2017)
Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia
Paolo Ghia et al.
BLOOD (2017)
Small-Molecule PROTACS: New Approaches to Protein Degradation
Momar Toure et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Romualdo Barroso-Sousa et al.
BREAST CARE (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Targeting CDK4/6 in patients with cancer
Erika Hamilton et al.
CANCER TREATMENT REVIEWS (2016)
New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities
Peng Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
John E. Bisi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Ping Chen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Concepcion Sanchez-Martinez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Ryan D. Cassaday et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
Ruben Niesvizky et al.
LEUKEMIA & LYMPHOMA (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
Cong Li et al.
MOLECULAR CANCER THERAPEUTICS (2015)
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
Sadhna R. Vora et al.
CANCER CELL (2014)
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
Monica M. Mita et al.
CLINICAL BREAST CANCER (2014)
LINE-1 Hypomethylation, DNA Copy Number Alterations, and CDK6 Amplification in Esophageal Squamous Cell Carcinoma
Yoshifumi Baba et al.
CLINICAL CANCER RESEARCH (2014)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3
Zhihong Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARKS)
M. V. Ramana Reddy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The Molecular Balancing Act of p16INK4a in Cancer and Aging
Kyle M. LaPak et al.
MOLECULAR CANCER RESEARCH (2014)
Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
Kathleen Keegan et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
Joe J. Stephenson et al.
LUNG CANCER (2014)
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Shuhui Lim et al.
DEVELOPMENT (2013)
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
Prithviraj Bose et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
Mark A. Dickson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure-Activity Relationship, and Anticancer Activities
Hao Shao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
John J. Nemunaitis et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard et al.
BLOOD (2012)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression
Subhashini Sadasivam et al.
GENES & DEVELOPMENT (2012)
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
Patrick J. Roberts et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Gerhard Siemeister et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors
Young Shin Cho et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Marieke Aarts et al.
CANCER DISCOVERY (2012)
Phosphorylation of human DNMT1: Implication of cyclin-dependent kinases
Genevieve Lavoie et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
The meaning of p16ink4a expression in tumors Functional significance, clinical associations and future developments
Agnieszka K. Witkiewicz et al.
CELL CYCLE (2011)
Discovery of Novel Thieno[2,3-d]pyrimidin-4-yl Hydrazone-Based Cyclin-Dependent Kinase 4 Inhibitors: Synthesis, Biological Evaluation and Structure-Activity Relationships
Takao Horiuchi et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2011)
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
D. S. Boss et al.
ANNALS OF ONCOLOGY (2010)
Cyclin-C-dependent cell-cycle entry is required for activation of non-homologous end joining DNA repair in postmitotic neurons
A. Tomashevski et al.
CELL DEATH AND DIFFERENTIATION (2010)
Discovery and Characterization of 2-Anilino-4-(Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents
Shudong Wang et al.
CHEMISTRY & BIOLOGY (2010)
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
Christophe Le Tourneau et al.
EUROPEAN JOURNAL OF CANCER (2010)
Cell Cycle-dependent Regulation of the Forkhead Transcription Factor FOXK2 by CDK.Cyclin Complexes
Anett Marais et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
4-(Pyrazol-4-yl)-pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4/6
Young Shin Cho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
J. L. Dean et al.
ONCOGENE (2010)
Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: Synthesis, biological evaluation and structure-activity relationships. Part 2
Takao Horiuchi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: Synthesis, biological evaluation, and structure-activity relationships
Takao Horiuchi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated Liposarcomas
Antoine Italiano et al.
CLINICAL CANCER RESEARCH (2009)
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Kate F. Byth et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
N. Raje et al.
LEUKEMIA (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors - Influence of cyclin L isoforms on splice site selection
Pascal Loyer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Transcriptional regulation of the cyclin D1 gene at a glance
Eric A. Klein et al.
JOURNAL OF CELL SCIENCE (2008)
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Ron Firestein et al.
NATURE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Deborah L. Burkhart et al.
NATURE REVIEWS CANCER (2008)
Cdk1 is sufficient to drive the mammalian cell cycle
David Santamaria et al.
NATURE (2007)
A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers
D. Ross Camidge et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00
Kalpana S. Joshi et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9
Tadashi Shimamura et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition
Heshu Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Continuous ERK activation downregulates anti proliferative genes throughout G1 phase to allow cell-cycle progression
Takuya Yamamoto et al.
CURRENT BIOLOGY (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3
K Leslie et al.
CANCER RESEARCH (2006)
Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins
QY Yu et al.
ONCOGENE (2005)
INK4a/ARF:: A multifunctional tumor suppressor locus
NE Sharpless
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2005)
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
PL Toogood et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4
SN VanderWel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
2-anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: Synthesis, SAR analysis, X-ray crystallography, and biological activity
SD Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Cell signalling and the control of pre-mRNA splicing
C Shin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
1,7-Annulated indolocarbazoles as cyclin-dependent kinase inhibitors
RS Al-Awar et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors
C Sanchez-Martinez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Studies on cyclin-dependent kinase inhibitors:: Indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides
C Sanchez-Martinez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Novel, potent and selective cyclin D1/CDK4 inhibitors:: Indolo[6,7-a]pyrrolo[3,4-c]carbazoles
TA Engler et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada clinical trials group
CT Kouroukis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors
GX Zhu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy
G Freyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
SJ McClue et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Cyclin dependent kinases and cell cycle control
PM Nurse
BIOSCIENCE REPORTS (2002)
Structure-based generation of a new class of potent Cdk4 inhibitors:: New de novo design strategy and library design
T Honma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
A novel approach for the development of selective Cdk4 inhibitors: Library design based on locations of Cdk4 specific amino acid residues
T Honma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases
M Barvian et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
分享论文
